Fig. 4.

Anti-ESCC effects of CAR-T cells in vivo. (A-G) Anti-ESCC effects of CAR-T cells in KYSE150 xenograft model. NSG mice were inoculated subcutaneously with 1 × 10⁶ FFluc⁺ KYSE150 cells at day −5 and given a single injection of purified 2 × 10⁶ CAR-T cells via tail veins at day 0 (A). Another 5 days later, FACS was performed to determine expansion (B), just as well as CD107a (C) and IFN-γ (D) expressions of tumor-infiltrating CAR-T cells (n = 5 in each group). Meanwhile, tumor growth was measured by bioluminescence photometry and flux values (photons per second) were calculated using Living Image software weekly (E and F). Mouse survival was recorded (G). Each group had 5 mice. (H-K) Anti-ESCC effects of CAR-T cells in the EC109 xenograft model. NSG mice were inoculated subcutaneously with 5 × 10⁶ FFluc⁺EC109 cells at day −7 and given 2 × 10⁶ CAR-T cells once via tail veins at day 0 (5 mice per group) (H). Then tumor growth was measured by bioluminescence photometry weekly (I-J). Survival of mice was recorded (K). Survival curves were compared by Log-rank test following Bonferroni correction. **, P < 0.01; ***, P < 0.005.